Study on the relationship between allogeneic blood transfusion and infection in patients with malignant lymphoma
-
-
Key words:
- malignant lymphoma /
- allogeneic blood transfusion /
- infection /
- correlation
-
表 1 输血组与非输血组患者资料比较
例(%),X±S 输血组
(36例)非输血组
(126例)P 年龄/岁 48.6±8.4 42.1±7.3 < 0.05 住院天数/d 47.3±11.2 19.6±8.8 < 0.05 性别 < 0.05 男 14(38.9) 79(62.7) 女 22(61.1) 47(37.3) 临床分期 < 0.05 Ⅰ~Ⅱ期 6(16.7) 60(47.6) Ⅲ~Ⅳ期 30(83.3) 66(52.4) 是否有侵入性治疗 < 0.05 是 24(66.7) 19(15.1) 否 12(33.3) 107(84.9) 是否使用抗菌药物 < 0.05 是 28(77.8) 27(21.4) 否 8(22.2) 99(78.6) 是否放疗或化疗 < 0.05 是 28(77.8) 2(1.6) 否 8(22.2) 124(98.4) 表 2 感染组与非感染组患者资料比较
例(%),X±S 感染
(51例)无感染
(111例)P 年龄/岁 45.1±10.3 44.2±7.9 >0.05 住院天数/d 38.5±12.4 26.3±8.3 < 0.05 性别 >0.05 男 28(54.9) 65(58.6) 女 23(45.1) 46(41.4) 临床分期 >0.05 Ⅰ~Ⅱ期 20(39.2) 46(41.4) Ⅲ~Ⅳ期 31(60.8) 65(58.6) 是否有侵入性治疗 >0.05 是 17(33.3) 26(23.4) 否 34(66.7) 85(76.6) 是否使用抗菌药物 >0.05 是 16(31.4) 39(35.1) 否 35(68.6) 72(64.9) 是否放疗或化疗 < 0.05 是 22(43.1) 8(7.2) 否 29(56.9) 103(92.8) 表 3 输血与感染的优势比较
例(%) 感染 输血组
(36例)非输血组
(126例)P OR 95%CI 是
否20(55.6)
16(44.4)31(24.6)
95(75.4)0.001 3.83 1.77~8.29 表 4 感染多变量logistic回归分析
例(%) 感染 OR
(调整后)P 95%CI 年龄(< 45 vs ≥45) 1.21 0.75 0.68~3.33 性别(男vs女) 1.12 0.76 0.65~3.05 住院天数(< 30 vs ≥30) 1.45 0.14 0.88~3.45 临床分期(Ⅰ~Ⅱ vs Ⅲ~Ⅳ) 1.22 0.72 0.65~3.18 输血vs未输血 3.66 0.01 1.51~8.74 侵入性治疗 1.43 0.18 0.85~2.76 使用抗菌药物 1.37 0.25 0.81~2.99 放疗或化疗 2.95 0.03 1.26~5.94 -
[1] 孙庆芬, 于莉, 段秀琴, 等. 集束化干预预防恶性血液病患者医院感染的效果[J]. 中国感染控制杂志, 2020, 19(2): 137-142. https://www.cnki.com.cn/Article/CJFDTOTAL-GRKZ202002008.htm
[2] 许惠丽, 张晓丽, 李楠, 等. 恶性淋巴瘤医院感染患者病原学特点及感染因素分析[J]. 中华医院感染学杂志, 2017, 27(19): 4431-4434. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201719030.htm
[3] Youssef LA, Spitalnik SL. Transfusion-related immunomodulation: a reappraisal[J]. Curr Opin Hematol, 2017, 24(6): 551-557. doi: 10.1097/MOH.0000000000000376
[4] Kim JL, Park JH, Han SB, et al. Allogeneic Blood Transfusion Is a Significant Risk Factor for Surgical-Site Infection Following Total Hip and Knee Arthroplasty: A Meta-Analysis[J]. J Arthroplasty, 2017, 32(1): 320-325. doi: 10.1016/j.arth.2016.08.026
[5] 邓倩, 唐亦舒, 成倩, 等. 恶性血液病患者革兰阳性菌血流感染的影响因素及预后分析[J]. 中华医院感染学杂志, 2018, 28(24): 3771-3775, 3803. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201824022.htm
[6] Newman ET, Watters TS, Lewis JS, et al. Impact of perioperative allogeneic and autologous blood transfusion on acute wound infection following total knee and total hip arthroplasty[J]. J Bone Joint Surg Am, 2014, 96(4): 279-284. doi: 10.2106/JBJS.L.01041
[7] Hart A, Khalil JA, Carli A, et al. Blood Transfusion in Primary Total Hip and Knee Arthroplasty. Incidence, Risk Factors, and Thirty-Day Complication Rates[J]. J Bone Joint Surg Am, 2014, 96(23): 1945-1951. doi: 10.2106/JBJS.N.00077
[8] Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma[J]. N Engl J Med, 2015, 372(4): 311-319. doi: 10.1056/NEJMoa1411087
[9] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-2917. doi: 10.1002/ijc.25516
[10] 陈万青, 郑荣寿, 张思维, 等. 2013年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2017, 26(1): 1-7. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU201701001.htm
[11] Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial[J]. Lancet Oncol, 2014, 15(1): 69-77. doi: 10.1016/S1470-2045(13)70551-5
[12] Ali S, Ali M, Badar F, et al. FACTORS ASSOCIATED WITH INCREASED RED BLOOD CELLS TRANSFUSION REQUIREMENTS IN PATIENTS WITH HODGKIN AND NON-HODGKIN LYMPHOMA[J]. J Ayub Med Coll Abbottabad, 2015, 27(1): 70-73.
[13] 曹琪, 戚晓梅. 恶性淋巴瘤PICC导管相关性血流感染患者NLR、D-二聚体等因子的表达及其意义[J]. 现代医学, 2018, 46(10): 1098-1102. doi: 10.3969/j.issn.1671-7562.2018.10.002
[14] 陈志, 周凯, 王端, 等. 髋、膝关节置换术围手术期尿路感染的病原菌构成及药物敏感性分析[J]. 华西医学, 2017, 32(9): 1387-1390. https://www.cnki.com.cn/Article/CJFDTOTAL-HXYX201709018.htm
[15] 田丰. 异体红细胞输注与脊柱手术术后医院感染的相关性[J]. 临床骨科杂志, 2018, 21(1): 25-28. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGK201801010.htm
[16] 蒋中艳, 刘龙娣, 王翀, 等. 异体红细胞输注对胸腰椎手术术后感染影响的研究[J]. 中华医院感染学杂志, 2019, 29(15): 2339-2342, 2352. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201915024.htm
[17] Taneja A, El-Bakoury A, Khong H, et al. Association between Allogeneic Blood Transfusion and Wound Infection after Total Hip or Knee Arthroplasty: A Retrospective Case-Control Study[J]. J Bone Jt Infect, 2019, 4(2): 99-105.
[18] 李毓龙, 黄倩倩, 李阳超. 髋关节置换术后同种异体输血与伤口感染的关系研究[J]. 临床血液学杂志, 2020, 33(4): 264-267. http://lcxz.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=3d1ef18c-99c2-49c2-83fb-532a743c04f3
[19] Almizraq RJ, Seghatchian J, Acker JP. Extracellular vesicles in transfusion-related immunomodulation and the role of blood component manufacturing[J]. Transfus Apher Sci, 2016, 55(3): 281-291.
[20] Goubran H, Sheridan D, Radosevic J, et al. Transfusion-related immunomodulation and cancer[J]. Transfus Apher Sci, 2017, 56(3): 336-340.